VRAY
ViewRay, Inc. [VRAY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
VRAY Stock Summary
In the News
VRAY Financial details
Company Rating
-
Market Cap
4.59M
Income
-114.17M
Revenue
105.87M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
295
Optionable
No
Shortable
Yes
Earnings
30 Oct 2023
P/E
-0.05
Forward P/E
-
PEG
0.16
P/S
0.05
P/B
0.08
P/C
-
P/FCF
-0.05
Quick Ratio
0.77
Current Ratio
1.16
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.63
EPS next Y
-
EPS next Q
-
EPS this Y
-7.69%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-8.59%
Revenue last 5Y
4.77%
Revenue Q/Q
-35.05%
EPS Q/Q
13.33%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-37%
ROE
-108%
ROC
-1.2%
Gross Margin
9%
Oper. Margin
-95%
Profit Margin
-104%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.025-4.96
52W High
-
52W Low
-
RSI
-
Rel Volume
7.36
Avg Volume
13.06M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.695696
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 13.06M
- Market Capitalization 4.59M
- Employee 295
- CEO Mr. Paul Ziegler Jr., J.D.
- Headquarters Oakwood,OH,US
- IPO Date 2015-08-10
-
Website
https://www.viewray.com 
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
